2/6 net-positive signal despite one significant setback.
The standout: riliprubart advanced to Phase 3 in chronic inflammatory demyelinating polyneuropathy (CIDP), now active and no longer recruiting—a sign of mature patient enrollment and readiness for pivotal testing.
The standout: riliprubart advanced to Phase 3 in chronic inflammatory demyelinating polyneuropathy (CIDP), now active and no longer recruiting—a sign of mature patient enrollment and readiness for pivotal testing.
August 11, 2026 at 1:25 PM
2/6 net-positive signal despite one significant setback.
The standout: riliprubart advanced to Phase 3 in chronic inflammatory demyelinating polyneuropathy (CIDP), now active and no longer recruiting—a sign of mature patient enrollment and readiness for pivotal testing.
The standout: riliprubart advanced to Phase 3 in chronic inflammatory demyelinating polyneuropathy (CIDP), now active and no longer recruiting—a sign of mature patient enrollment and readiness for pivotal testing.
Sanofi's MOBILIZE Phase 3 trial of riliprubart in refractory CIDP has been halted on efficacy grounds. An independent monitoring committee determined the study is unlikely to meet its primary endpoint. No safety signals emerged.
Sanofi halts MOBILIZE Phase 3 trial of riliprubart in refractory CIDP
An independent data monitoring committee found the study unlikely to demonstrate sufficient efficacy; no safety concerns were identified with riliprubart.
biotech.disruptsmedia.com
June 23, 2026 at 9:00 AM
Sanofi's MOBILIZE Phase 3 trial of riliprubart in refractory CIDP has been halted on efficacy grounds. An independent monitoring committee determined the study is unlikely to meet its primary endpoint. No safety signals emerged.
The Rising Market for Chronic Inflammatory Demyelinating Polyneuropathy Amidst New Therapies and Awareness Efforts#None#CIDP#Batoclimab#Riliprubart
The Rising Market for Chronic Inflammatory Demyelinating Polyneuropathy Amidst New Therapies and Awareness Efforts
The chronic inflammatory demyelinating polyneuropathy market is set to grow significantly by 2036, driven by increased awareness, improved diagnoses, and promising new therapies.
third-news.com
June 18, 2026 at 2:37 PM
The Rising Market for Chronic Inflammatory Demyelinating Polyneuropathy Amidst New Therapies and Awareness Efforts#None#CIDP#Batoclimab#Riliprubart
Feed: "Clinical Trials Arena"
By: Abigail Beaney on Wednesday, June 10, 2026
By: Abigail Beaney on Wednesday, June 10, 2026
Sanofi terminates Phase III CIPD trial due to low efficacy
While Sanofi’s study of riliprubart in CIPD has been terminated, another study will continue.
www.clinicaltrialsarena.com
June 10, 2026 at 9:48 PM
Feed: "Clinical Trials Arena"
By: Abigail Beaney on Wednesday, June 10, 2026
By: Abigail Beaney on Wednesday, June 10, 2026
Findings from an interim analysis of rilipruart showed that the study was unlikely to meet the efficacy threshold. https://www.empr.com/news/sanofi-halts-riliprubart-cidp-trial/
Sanofi Ends Phase 3 MOBILIZE Trial of Riliprubart for CIDP
Sanofi is stopping the phase 3 MOBILIZE clinical trial evaluating riliprubart in adult patients with chronic inflammatory demyelinating polyneuropathy who are refractory to standard therapies.
www.empr.com
June 10, 2026 at 7:51 PM
Findings from an interim analysis of rilipruart showed that the study was unlikely to meet the efficacy threshold. https://www.empr.com/news/sanofi-halts-riliprubart-cidp-trial/
Sanofi ends Phase 3 riliprubart trial after weak interim results reut.rs/4aCQ3m8
Sanofi ends Phase 3 riliprubart trial after weak interim results
Biopharmaceutical company Sanofi will stop a Phase 3 trial of its drug riliprubart for a rare neurological condition after an interim analysis of the study found it unlikely to provide sufficient efficacy.
reut.rs
June 10, 2026 at 11:35 AM
Sanofi ends Phase 3 riliprubart trial after weak interim results reut.rs/4aCQ3m8
#$SNY discontinues its Phase 3 MOBILIZE study of riliprubart in refractory CIDP after failing to show efficacy. The setback raises major doubts for #$DNTH claseprubart (C1s inhibitor). notreload.xyz/xy/sanofi-dr...
Sanofi Drops Phase 3 Riliprubart Trial in CIDP, Dianthus Plunges
Sanofi discontinues its Phase 3 MOBILIZE study of riliprubart in refractory CIDP after failing to show efficacy. The setback raises major doubts for Dianthus’ claseprubart (C1s inhibitor).
notreload.xyz
June 10, 2026 at 11:02 AM
#$SNY discontinues its Phase 3 MOBILIZE study of riliprubart in refractory CIDP after failing to show efficacy. The setback raises major doubts for #$DNTH claseprubart (C1s inhibitor). notreload.xyz/xy/sanofi-dr...
#Sanofi's #neurology pipeline has had a hole blown in it after a phase 3 trial of #riliprubart (SAR445088) in #raredisease chronic inflammatory demyelinating polyneuropathy (#CIDP) was stopped for futility.
pharmaphorum.com/news/sanofi-...
pharmaphorum.com/news/sanofi-...
Sanofi abandons phase 3 trial of neurology drug riliprubart
Sanofi's neurology pipeline has had a hole blown in it after a phase 3 trial of riliprubart in rare disease CIDP was stopped for futility.
pharmaphorum.com
June 10, 2026 at 9:40 AM
#Sanofi's #neurology pipeline has had a hole blown in it after a phase 3 trial of #riliprubart (SAR445088) in #raredisease chronic inflammatory demyelinating polyneuropathy (#CIDP) was stopped for futility.
pharmaphorum.com/news/sanofi-...
pharmaphorum.com/news/sanofi-...
Biopharmaceutical company Sanofi will stop a Phase 3 trial of its drug riliprubart for a rare neurological condition after an interim analysis of the study found it unlikely to provide sufficient efficacy.
Sanofi ends Phase 3 riliprubart trial after weak interim results
Biopharmaceutical company Sanofi will stop a Phase 3 trial of its drug riliprubart for a rare neurological condition after an interim analysis of the study found it unlikely to provide sufficient efficacy.
reut.rs
June 10, 2026 at 7:00 AM
Biopharmaceutical company Sanofi will stop a Phase 3 trial of its drug riliprubart for a rare neurological condition after an interim analysis of the study found it unlikely to provide sufficient efficacy.
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/52724...
February 3, 2026 at 5:23 AM
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/52724...
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/52724...
February 3, 2026 at 1:07 AM
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/52724...
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/50512...
December 23, 2025 at 7:02 AM
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/50512...
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/50512...
December 23, 2025 at 4:31 AM
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/50512...
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/50512...
December 23, 2025 at 3:27 AM
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/50512...
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/50512...
December 23, 2025 at 3:21 AM
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/50512...
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/50512...
December 23, 2025 at 3:16 AM
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/50512...
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/50512...
December 23, 2025 at 3:15 AM
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/50512...
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/50512...
December 23, 2025 at 2:12 AM
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/50512...
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/50512...
December 23, 2025 at 1:43 AM
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/50512...
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/47927...
November 2, 2025 at 9:59 AM
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/47927...
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/47927...
November 2, 2025 at 2:21 AM
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/47927...
FDA присвоило статус орфанного препарата Riliprubart компании Sanofi: новые горизонты в лечении редких заболеваний
https://kripta.biz/posts/CD5CD490-B400-4CB0-BA8C-F3E88C44E13C
https://kripta.biz/posts/CD5CD490-B400-4CB0-BA8C-F3E88C44E13C
October 10, 2025 at 8:44 PM
FDA присвоило статус орфанного препарата Riliprubart компании Sanofi: новые горизонты в лечении редких заболеваний
https://kripta.biz/posts/CD5CD490-B400-4CB0-BA8C-F3E88C44E13C
https://kripta.biz/posts/CD5CD490-B400-4CB0-BA8C-F3E88C44E13C
赛诺菲新药Riliprubart获FDA孤儿药资格 助力罕见移植排斥反应治疗迎来新希望
https://qian.cx/posts/C910B87F-2E93-4416-840A-6971B1912DFB
https://qian.cx/posts/C910B87F-2E93-4416-840A-6971B1912DFB
October 10, 2025 at 8:44 PM
赛诺菲新药Riliprubart获FDA孤儿药资格 助力罕见移植排斥反应治疗迎来新希望
https://qian.cx/posts/C910B87F-2E93-4416-840A-6971B1912DFB
https://qian.cx/posts/C910B87F-2E93-4416-840A-6971B1912DFB